Randomized, Double-Blind, Placebo-Controlled Study and Open-Label Extension of Liposomal Amikacin for Inhalation (LAI) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease (NTM-LD)

Liposomal Amikacin for Inhalation (LAI) in Patients with Recalcitrant Nontuberculous Mycobacterial Lung Disease (NTM-LD) Kenneth N. Olivier1, Renu Gupta2, Gina Eagle 2, John P. McGinnis II2, Liza Micioni2, Charles L. Daley3, Kevin L.Winthrop4, Stephen Ruoss5, Doreen J. Addrizzo-Harris6, PatrickFlume7, Daniel Dorgan8, Matthias Salathe9, Barbara A. Brown-Elliott10,Richard Wallace10, David E. Griffith10